2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

Saved in:

Bibliographic Details
Published in	Arthritis & rheumatology (Hoboken, N.J.) Vol. 65; no. 1; pp. 1 - 11
Main Authors	Jennette, J. C., Falk, R. J., Bacon, P. A., Basu, N., Cid, M. C., Ferrario, F., Flores‐Suarez, L. F., Gross, W. L., Guillevin, L., Hagen, E. C., Hoffman, G. S., Jayne, D. R., Kallenberg, C. G. M., Lamprecht, P., Langford, C. A., Luqmani, R. A., Mahr, A. D., Matteson, E. L., Merkel, P. A., Ozen, S., Pusey, C. D., Rasmussen, N., Rees, A. J., Scott, D. G. I., Specks, U., Stone, J. H., Takahashi, K., Watts, R. A.
Format	Journal Article
Language	English
Published	Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2013 Wiley Subscription Services, Inc
Subjects	Humans Vasculitis - classification Vasculitis - diagnosis
Online Access	Get full text
ISSN	0004-3591 2326-5191 1529-0131 1529-0131 2326-5205
DOI	10.1002/art.37715

More Information
Bibliography:	Dr. Luqmani has received consulting fees, speaking fees, and/or honoraria from Human Genome Sciences (less than $10,000) and from Nordic Pharma and ChemoCentryx (more than $10,000 each). Dr. Hoffman has received consulting fees, speaking fees, and/or honoraria from Genentech and Sanofi‐Aventis (less than $10,000 each). Dr. Rees has received consulting fees, speaking fees, and/or honoraria from Baxter Innovations Vienna, and Proximagen (less than $10,000 each). Dr. Guillevin has received consulting fees from Roche, GlaxoSmithKline, and Actelion Pharma (less than $10,000 each). Dr. Scott has received speaking fees and honoraria for advisory committee/board service from Roche (less than $10,000). Dr. Ozen has received consulting fees from Novartis Turkey (less than $10,000) and speaking fees from Swedish Orphan Biovitrum (less than $10,000). ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-News-3 ObjectType-Conference-4 ObjectType-News-1 ObjectType-Feature-4 ObjectType-Conference-2 content type line 23 ObjectType-Article-3
ISSN:	0004-3591 2326-5191 1529-0131 1529-0131 2326-5205
DOI:	10.1002/art.37715